---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000114"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:25:01.108904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023

## Summary
- Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.
- Phase 2 trial of batoclimab in Graves' Disease to start early 2023; initial results expected H2 2023.
- Batoclimab now in five indications: MG, TED, CIDP, Graves', and wAIHA (trial design pending regulator interaction later 2022).
- Data readouts expected every half-year from H2 2023 through H1 2025 across multiple indications.

## SEC filing metadata
- accession: 0001764013-22-000114
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/0001764013-22-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/imvt-20220907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000114
- JSON: https://secwatch.observer/filing/0001764013-22-000114.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.